Nykode Therapeutics Asa · OSL:NYKD
Nykode Therapeutics Asa — Q1 2026 Earnings Presentation
27 slides from Nykode Therapeutics Asa's earnings presentation, May 27, 2026
Slide 1: Q1 2026 Results Presentation
Q1 2026 Results Presentation May 27, 2026
Slide 2: Forward-looking statement
Forward-looking statement This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumpt
Slide 3: Today's presenters from Nykode
Today’s presenters from Nykode MICHAEL ENGSIG AGNETE FREDRIKSEN HARALD GURVIN Chief Executive Officer Chief Scientific Officer & Chief Financial Officer Business Development Nykode Therapeutics | Q1 '26 webcast | Non-confidential 3
Slide 4: Nykode Therapeutics - Highlights
Nykode Therapeutics - Highlights NYKODE THERAPEUTICS (OSE: NYKD.OL) APC-targeted immunotherapy platform Precision immune activation for oncology and immune modulation for autoimmune diseases Lead asset: Abi-Suva 1L head & neck cancer program supported by prior clinical data across ~100 patients
Slide 5: Highlights
Highlights First patient dosed in Abili-T Abili-T multiple sites activated 38.5% ORR vs. 19% SoC presented at ICHNO in March VB-C-03 interim data shows significantly higher ORR compared to standard of care. This is supported by two previous studies showing promising efficacy and safety data (VB-C-01
Slide 6: Abi-suva
Abi-suva Nykode Therapeutics | Q1 '26 webcast | Non-confidential 6
Slide 7: The current focus of abi-suva is 1L r/m HNSCC with the potential to expand
The current focus of abi-suva is 1L r/m HNSCC with the potential to expand to additional indications and lines of treatment Current focus of abi-suva Future potential for abi-suva 1L r/m HNSCC HPV16+ driven cancers Incidence of HPV16+ driven HNSCC cancers Incidence of HPV16+ driven cancers in EU in
Slide 8: Abi-suva shows strong and consistent clinical effect across several trials and HPV16 driven indications
Abi-suva shows strong and consistent clinical effect across several trials and HPV16 driven indications Consistent overall response rate (ORR) improvement compared to CPI monotherapy across indications Objective response rate (ORR) of abi-suva in combination with CPI compared to historical CPI monot
Slide 9: Abi-suva induced HPV16 E6 and/or E7 specific T cell responses in 10/11 patients
Abi-suva induced HPV16 E6 and/or E7 specific T cell responses in 10/11 patients ➢ HPV16-specific immune responses were observed in all analyzed participants receiving either 6 mg or 9 mg of abi-suva. ➢ The vaccine-induced HPV16 E6/E7 responses were robust, as demonstrated by high magnitude and stron
Slide 10: First patient dosed in randomized Phase 2 Abili-T trial with first interim data expected in 2027
First patient dosed in randomized Phase 2 Abili-T trial with first interim data expected in 2027 Trial design Key inclusion criterion Treatment Endpoints ORR Abipapogene suvaplasmid + pembrolizumab PFS • HPV16+ r/m HNSCC DOR • PD-L1+ R RMDOR • Measurable disease (1:1) DCR • ECOG PS 0-1 OS • GRIm 0-1
Slide 11: VB10.NEO
VB10.NEO Nykode Therapeutics | Q1 '26 webcast | Non-confidential 11
Slide 12: VB10.NEO is well positioned in the field of individualized neoantigen therapies
Peer readouts within next 12 months can create a strong conviction for INTs VB10.NEO is well positioned in the field of VB10.NEO meets requirement for ideal individualized neoantigen INT technology therapies Continuing to strengthen this position with key activities focused on further optimizing rob
Slide 13: VB10.NEO delivers on all key success factors for an ideal INT candidate
VB10.NEO delivers on all key success factors for an ideal INT candidate Focus in Q1 Clinical Antigen selection Supply chain Costs experience NeoSELECT – Nykode has a Nykode’s DNA based Nykode’s two Nykode’s robust and proven therapy has both clinical trials show proprietary supply chain with advance
Slide 14: Tolerance
Tolerance Nykode Therapeutics | Q1 '26 webcast | Non-confidential 14
Slide 15: Key highlights of Nykode's APC ASIT Technology
Key highlights of Nykode’s APC ASIT Technology Strong and durable efficacy across disease models – therapeutic and preventative Modular APC-targeting platform allows unique customization for tailored immune control Unprecedented induction of antigen-specific regulatory T cells, suppression of effect
Slide 16: Induction of antigen-specific immune tolerance by targeting disease causing epitopes to specific APCs
Induction of antigen-specific immune tolerance by targeting disease causing epitopes to specific APCs TARGETING SPECIFIC TOLERANCE INDUCTION APC-targeted B cells Effector Therapy B cell APCs Regulatory Regulatory T cell T cell Dendritic cells Macrophages Effector T cell Anergy or Deletion 1 Distinct
Slide 17: Human translational data
17 Human translational data Nykode’s APC- targeted therapy binds and improves Ag presentation Binding of Nykode’s Targeted Therapy to human APCs Nykode’s targeted facilitation of Ag presentation on human APCs APC APC Targeted APC Non-targeted Therapy Therapy Irrelevant Ag 1000 nM Non-targeted APC AP
Slide 18: Differentiated APC-targeting enables distinct Ag-specific proliferation and induction of regulatory T cells
18 Differentiated APC-targeting enables distinct Ag-specific proliferation and induction of regulatory T cells MOG (27-63) DIFFERENTIATED PROLIFERATION AND REGULATION OF IMMUNE RESPONSE APC Non-targeted Therapy Targeted 5 ✱✱✱✱ ✱✱✱✱ Targeted 5 10 of CD4+Thy1.2+ T cells Targeted 4 Targeted 4 Targeted
Slide 19: AI driven drug design
AI driven drug design Nykode Therapeutics | Q1 '26 webcast | Non-confidential 19
Slide 20: How AI is Embedded in Nykode's Platform
How AI is Embedded in Nykode’s Platform Our Competitive Differentiation Utilizing AI NeoSELECT Construct Screening Predictive Design VB10.NEO Platform-wide Quality Assurance Proprietary AI algorithm selects the AI-driven design and screening Predictive modeling improves construct quality most immuno
Slide 21: Q1 2026 Financial Results
Q1 2026 Financial Results Nykode Therapeutics | Q1 '26 webcast | Non-confidential 21
Slide 22: Income Statement
Income Statement Other income Amounts in USD ‘000 Q1 2026 Q1 2025 FY 2025 • Government grants from SkatteFUNN Other income 240 137 453 Employee benefit expenses Total other income 240 137 453 • Decrease in 2026 mainly due to reduced Employee benefit expenses 2,873 3,708 13,552 organization Other ope
Slide 23: Balance Sheet
Balance Sheet Cash and cash equivalents Amounts in USD ‘000 31/03/2026 31/12/2025 • Cash position of $51.3m at March 31, 2026 ASSETS Other non-current receivables Non-current assets • Mainly reflects the NOK 325m payment to the Property, plant and equipment 2,868 3,044 Norwegian Tax Authorities (NTA
Slide 24: Balance Sheet - contd.
Balance Sheet - contd. Amounts in USD ’000 31/03/2026 31/12/2025 Equity EQUITY AND LIABILITIES • Total equity of $87.5m as per March 31, 2026 Equity Share capital 367 367 • Equity ratio of 93% Share premium 96,707 96,707 Other capital reserves 18,666 18,653 Other components of equity (2,930) (3,006)
Slide 25: Outlook and closing remarks
Outlook and closing remarks Nykode Therapeutics | Q1 '26 webcast | Non-confidential 25
Slide 26: Well-positioned to execute strategy and meet inflection points
Well-positioned to execute strategy and meet inflection points Cash runway Next 12 months Next 12-24 months Cash runway into 2028-2029* Expand the number of countries Abili-T first interim analysis (2027) and sites in Abili-T trial Cash runway exceeding Continued expected key peer significant inflec
Slide 27: Q&A
Q&A • Michael Engsig, CEO • Agnete Fredriksen, CSO and Business Development • Harald Gurvin, CFO Nykode Therapeutics | Q1 ‘26 webcast | Non-confidential 27